Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

The Impact of Indoor Environmental Quality on Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD-AIR)

27 de agosto de 2026 atualizado por: Ziekenhuis Oost-Limburg

The Impact of Indoor Environmental Quality on Symptoms in Patients With Chronic Obstructive Pulmonary Disease: A Prospective Pilot Study

This prospective, monocenter pilot study will investigate the relationship between indoor environmental quality (including air quality, lighting, noise, and thermal conditions), wearable-derived health insights, and patient-reported symptoms in patients recovering at home after hospitalization for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Participants will undergo continuous monitoring of indoor environmental conditions and health parameters using a Garmin Venu 4 smartwatch, together with validated questionnaires assessing COPD symptoms, sleep quality, and daytime sleepiness during one month. The study will assess the feasibility and potential added value of high-resolution home monitoring and explore whether environmental and wearable-derived measures are associated with symptom burden and early signs of clinical deterioration following hospital discharge.

The investigators hypothesize that continuous in-home monitoring of indoor environmental quality is feasible and provides clinically relevant insights into symptom burden in recently hospitalized COPD patients. The primary objective is to determine the correlation between indoor environmental quality (IEQ) variables and symptom burden in COPD patients following hospitalization for AECOPD.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

Patients hospitalized for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) remain highly vulnerable after discharge, with persistent symptom burden and an increased risk of early recurrent exacerbations. During this post-hospitalization period, patients spend most of their time indoors, making indoor environmental quality (IEQ, including air quality, lighting, noise and thermal aspects) a potentially important and modifiable determinant of recovery. For example, exposure to particulate matter (PM) has been associated with airway inflammation, symptom worsening, and increased exacerbation risk in COPD. However, evidence on continuously measured IEQ at home and its relationship with symptoms after hospitalization for acute exacerbation of COPD remains limited.

Recent advances in wearable technology allow continuous monitoring of health insights in real-world settings. Prior studies have demonstrated the feasibility of wearable devices in patients with COPD and suggest that changes in activity, heart rate, and sleep may precede clinical deterioration or exacerbations. Integrating continuous IEQ monitoring with wearable-derived health insights (i.e., from a Garmin Venu 4 watch) and validated patient-reported outcomes, such as the widely used COPD Assessment Test (CAT), Pittsburgh Sleep Quality Index (PSQI), Karolinska Sleepiness Scale (KSS), Sleep Quality Scale (SQS), may improve understanding of symptom dynamics, uncover risk factors, and identify early indicators of worsening disease. This prospective monocenter pilot study aims to explore these relationships and to assess the feasibility and added value of high-resolution IEQ monitoring in the home setting of recently hospitalized COPD patients.

Tipo de estudo

Intervencional

Inscrição (Estimado)

15

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

  • Bélgica
      • Genk, Bélgica, 3600
        • Ziekenhuis Oost-Limburg
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • Provide signed and dated informed consent
  • Adults older than 18 years of age
  • Previously diagnosed with COPD according to GOLD guidelines
  • Hospitalization due to AECOPD
  • Spend >50% of time indoor at home
  • Speak and understand the Dutch language

Exclusion Criteria:

  • Previous diagnosis of asthma
  • (History of) chronic macrolide use (> 3 months)
  • Living in institution or residential care center
  • Estimated life expectancy of less than 6 months
  • Not in the possession of a smartphone

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Patients admitted with an acute COPD exacerbation
Wearable mobile device (Garmin Venu) & Indoor environmental quality sensor
Dispositivo: Wearable mobile device
Patients admitted due to an acute COPD exacerbation will be asked to wear the wearable mobile device for a period of one month after hospital discharge. An app linked to the device will be installed on their phone, and used to send health insights to the investigators.
Outros nomes:
  • Garmin Venu
Dispositivo: Indoor environmental quality sensor
When the participants are discharged home, an indoor environmental quality sensor will be installed in the patient's home. One sensor will be installed in the bedroom, one in the living room or kitchen (wherever the patient spends the most time). Data from these sensors will be sent to the hub (placed central between the sensors) and thereafter, to the investigators. The sensors measure particulate matter concentrations, CO2 concentrations, VOC concentrations, temperature, relative humidity, ambient light, and ambient noise.
Outro: CAT Questionnaire
A COPD Assessment Test questionnaire will be taken during the hospitalization (start of the study), and weekly after discharge.
Outro: PSQI Questionnaire
A Pittsburgh Sleep Quality Index questionnaire will be taken 4 weeks after hospital discharge (end of the study).
Outro: KSS Questionnaire
A Karolinska Sleepiness Scale questionnaire will be taken daily after discharge.
Outro: SQS Questionnaire
A sleep quality scale questionnaire will be taken daily after discharge.
Outro: PROMs Questionnaire
A PROMs questionnaire will be taken daily after discharge.
Outro: eHLQ Questionnaire
An eHealth literacy questionnaire will be taken during the hospitalization (start of the study), and 4 weeks after hospital discharge (end of the study).
Outro: Housing Questionnaire
A housing questionnaire will be taken during the hospitalization (start of the study).

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Weekly score of COPD symptom burden assessed using the COPD Assessment Test (CAT)
Prazo: Baseline and weekly during the 1-month follow-up
COPD symptom burden will be assessed using the COPD Assessment Test (CAT). The CAT is an 8-item questionnaire with a total score ranging from 0 to 40 points, with higher scores indicating greater COPD symptom burden and a greater impact of COPD on daily life.
Baseline and weekly during the 1-month follow-up
Weekly mean PM0.5 concentration
Prazo: Weekly during the 1-month follow-up
Indoor PM0.5 concentration (µg/m³) will be measured at 15-minute intervals in the participant's home during the 1-month follow-up. The measurements collected during each week will be aggregated to calculate a weekly mean PM0.5 concentration.
Weekly during the 1-month follow-up
Weekly mean PM2.5 concentration
Prazo: Weekly during the 1-month follow-up
Indoor PM2.5 concentration (µg/m³) will be measured at 15-minute intervals in the participant's home during the 1-month follow-up. The measurements collected during each week will be aggregated to calculate a weekly mean PM2.5 concentration.
Weekly during the 1-month follow-up
Weekly mean PM4 concentration
Prazo: Weekly during the 1-month follow-up
Indoor PM4 concentration (µg/m³) will be measured at 15-minute intervals in the participant's home during the 1-month follow-up. The measurements collected during each week will be aggregated to calculate a weekly mean PM4 concentration.
Weekly during the 1-month follow-up
Weekly mean PM10 concentration
Prazo: Weekly during the 1-month follow-up
Indoor PM10 concentration (µg/m³) will be measured at 15-minute intervals in the participant's home during the 1-month follow-up. The measurements collected during each week will be aggregated to calculate a weekly mean PM10 concentration.
Weekly during the 1-month follow-up
Weekly mean CO2 concentration
Prazo: Weekly during the 1-month follow-up
Indoor CO2 concentration (ppm) will be measured at 15-minute intervals in the participant's home during the 1-month follow-up. The measurements collected during each week will be aggregated to calculate a weekly mean CO2 concentration.
Weekly during the 1-month follow-up
Weekly mean VOC concentration
Prazo: Weekly during the 1-month follow-up
Indoor volatile organic compound (VOC) concentration (ppb) will be measured at 15-minute intervals in the participant's home during the 1-month follow-up. The measurements collected during each week will be aggregated to calculate a weekly mean VOC concentration.
Weekly during the 1-month follow-up
Weekly mean temperature
Prazo: Weekly during the 1-month follow-up
Indoor temperature concentration (°C) will be measured at 15-minute intervals in the participant's home during the 1-month follow-up. The measurements collected during each week will be aggregated to calculate a weekly mean temperature.
Weekly during the 1-month follow-up
Weekly mean relative humidity
Prazo: Weekly during the 1-month follow-up
Indoor relative humidity (%) will be measured at 15-minute intervals in the participant's home during the 1-month follow-up. The measurements collected during each week will be aggregated to calculate a weekly mean relative humidity.
Weekly during the 1-month follow-up
Weekly mean ambient light - day
Prazo: Weekly during the 1-month follow-up
Indoor ambient light (lux) will be measured at 15-minute intervals in the participant's home during the 1-month follow-up. The measurements collected during each week during day-time hours will be aggregated to calculate a weekly mean ambient light - day.
Weekly during the 1-month follow-up
Weekly mean ambient light - night
Prazo: Weekly during the 1-month follow-up
Indoor ambient light (lux) will be measured at 15-minute intervals in the participant's home during the 1-month follow-up. The measurements collected during each week during night-time hours will be aggregated to calculate a weekly mean ambient light - night.
Weekly during the 1-month follow-up
Weekly mean ambient noise - night
Prazo: Weekly during the 1-month follow-up
Indoor ambient noise (dB) will be measured at 15-minute intervals in the participant's home during the 1-month follow-up. The measurements collected during each week during night-time hours will be aggregated to calculate a weekly mean ambient noise - night.
Weekly during the 1-month follow-up
Weekly overall proportion of time with at least one IEQ threshold violated
Prazo: Weekly during the 1-month follow-up
Overall proportion of monitoring time per week during which at least one predefined indoor environmental quality (IEQ) threshold is violated. IEQ variables will be monitored at predefined measurement intervals during the 1-month follow-up. For each measurement time point, the IEQ variables will be compared with their respective predefined thresholds. The proportion of monitoring time points at which at least one IEQ threshold is violated will be calculated for each week.
Weekly during the 1-month follow-up

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Feasibility - Measurement completeness
Prazo: During follow-up (1 month)
Proportion of expected IEQ measurements successfully recorded.
During follow-up (1 month)
Feasibility - Valid monitoring time
Prazo: During follow-up (1 month)
Duration of valid monitoring time per participant.
During follow-up (1 month)
Daily perceived change in health status
Prazo: Daily during follow-up (1 month)
Patient-reported change in overall health status compared with the previous day, assessed using a single question: "How is your health today compared with yesterday?" Participants will select one of three response options: better, about the same, or worse.
Daily during follow-up (1 month)
Feasibility - Frequency of data gaps
Prazo: During follow-up (1 month)
Frequency of gaps in monitoring data.
During follow-up (1 month)
Feasibility - Duration of data gaps
Prazo: During follow-up (1 month)
Duration of gaps in monitoring data.
During follow-up (1 month)
Wearable-derived health insights - Heart rate
Prazo: Continuous monitoring during follow-up (1 month)
Heart rate (BPM) measured using the wearable.
Continuous monitoring during follow-up (1 month)
Wearable-derived health insights - Respiratory rate
Prazo: Continuous monitoring during follow-up (1 month)
Respiratory rate (BPM) measured using the wearable.
Continuous monitoring during follow-up (1 month)
Wearable-derived health insights - Oxygen saturation
Prazo: Continuous monitoring during follow-up (1 month)
Oxygen saturation (%) measured using the wearable.
Continuous monitoring during follow-up (1 month)
Wearable-derived health insights - Skin temperature
Prazo: Continuous monitoring during follow-up (1 month)
Nightly deviation in skin temperature (°C) compared with the previous night, measured using the wearable.
Continuous monitoring during follow-up (1 month)
Sleep quality - PSQI
Prazo: End of study (one month)
Pittsburgh Sleep Quality Index (PSQI) assessing subjective sleep quality over the preceding month. The PSQI total score ranges from 0 to 21 points, with higher scores indicating poorer sleep quality.
End of study (one month)
Sleepiness - KSS
Prazo: Daily during the 1-month follow-up
Karolinska Sleepiness Scale (KSS) assessing subjective sleepiness at a specific time point. The KSS score ranges from 1 to 9 points, with higher scores indicating greater subjective sleepiness.
Daily during the 1-month follow-up
Sleep quality - SQS
Prazo: Daily during the 1-month follow-up
Single-item Sleep Quality Scale (SQS) assessing perceived sleep quality of the previous night. The SQS score ranges from 0 to 10 points, with higher scores indicating better perceived sleep quality.
Daily during the 1-month follow-up
Wearable-derived sleep metrics - Sleep duration
Prazo: Nightly during the 1-month follow-up
Nightly sleep duration (hours) measured using the wearable.
Nightly during the 1-month follow-up
Wearable-derived sleep metrics - Sleep score
Prazo: Nightly during the 1-month follow-up
Nightly sleep score measured using the wearable. Score from 0-100, with a higher score indicating better quality of sleep.
Nightly during the 1-month follow-up
Wearable-derived sleep metrics - Time in sleep cycle
Prazo: Nightly during the 1-month follow-up
Nightly time spent in REM, deep, and light sleep (hours).
Nightly during the 1-month follow-up
Wearable-derived physical activity - Daily step count
Prazo: Daily during the 1-month follow-up
Daily step count (number) measured by the wearable.
Daily during the 1-month follow-up
Wearable-derived physical activity - Activity minutes
Prazo: Daily during the 1-month follow-up
Daily activity minutes (minutes) measured by the wearable.
Daily during the 1-month follow-up
Concentration of outside air quality
Prazo: During follow-up (1 month)
Concentration of outside air quality measure (PM, expressed in µg/m³) based on the participant's residential area.
During follow-up (1 month)
COPD exacerbations
Prazo: During follow-up (1 month)
Occurrence of a COPD exacerbation during the follow-up period.
During follow-up (1 month)
eHealth literacy
Prazo: Baseline and end of study (one month)
eHealth Literacy Questionnaire (eHLQ) domain scores describing participants' strengths and needs related to eHealth literacy. The eHLQ consists of 35 items across 7 domains. Each domain is scored from 1 to 4 points, with higher scores indicating a greater level of the characteristic assessed by the respective domain.
Baseline and end of study (one month)
Change in eHealth literacy
Prazo: Baseline and end of study (one month)
Change in eHealth literacy from baseline to the end of the 1-month follow-up, assessed using the eHealth Literacy Questionnaire (eHLQ). The eHLQ consists of 35 items across 7 domains. Each domain is scored from 1 to 4 points. Higher scores indicate a greater level of the characteristic assessed by the respective domain. Change in each domain score from baseline to 1 month will be calculated.
Baseline and end of study (one month)
Housing characteristics
Prazo: Baseline
Sociodemographic characteristics, housing characteristics, and indoor environmental factors assessed using the Housing Conditions Questionnaire.
Baseline
Weekly overall proportion of time with PM0.5 threshold exceeded
Prazo: Weekly during the 1-month follow-up
Overall proportion of monitoring time per week during which PM0.5 threshold is exceeded. PM0.5 will be monitored at predefined measurement intervals during the 1-month follow-up. For each measurement time point, PM0.5 will be compared with its respective predefined threshold. The proportion of monitoring time points at which PM0.5 is exceeded will be calculated for each week.
Weekly during the 1-month follow-up
Weekly overall proportion of time with PM1 threshold exceeded
Prazo: Weekly during the 1-month follow-up
Overall proportion of monitoring time per week during which PM1 threshold is exceeded. PM1 will be monitored at predefined measurement intervals during the 1-month follow-up. For each measurement time point, PM1 will be compared with its respective predefined threshold. The proportion of monitoring time points at which PM1 is exceeded will be calculated for each week.
Weekly during the 1-month follow-up
Weekly overall proportion of time with PM2.5 threshold exceeded
Prazo: Weekly during the 1-month follow-up
Overall proportion of monitoring time per week during which PM2.5 threshold is exceeded. PM2.5 will be monitored at predefined measurement intervals during the 1-month follow-up. For each measurement time point, PM2.5 will be compared with its respective predefined threshold. The proportion of monitoring time points at which PM2.5 is exceeded will be calculated for each week.
Weekly during the 1-month follow-up
Weekly overall proportion of time with PM4 threshold exceeded
Prazo: Weekly during the 1-month follow-up
Overall proportion of monitoring time per week during which PM4 threshold is exceeded. PM4 will be monitored at predefined measurement intervals during the 1-month follow-up. For each measurement time point, PM4 will be compared with its respective predefined threshold. The proportion of monitoring time points at which PM4 is exceeded will be calculated for each week.
Weekly during the 1-month follow-up
Weekly overall proportion of time with PM10 threshold exceeded
Prazo: Weekly during the 1-month follow-up
Overall proportion of monitoring time per week during which PM10 threshold is exceeded. PM10 will be monitored at predefined measurement intervals during the 1-month follow-up. For each measurement time point, PM10 will be compared with its respective predefined threshold. The proportion of monitoring time points at which PM10 is exceeded will be calculated for each week.
Weekly during the 1-month follow-up
Weekly overall proportion of time with CO2 threshold exceeded
Prazo: Weekly during the 1-month follow-up
Overall proportion of monitoring time per week during which the CO2 threshold is exceeded. CO2 will be monitored at predefined measurement intervals during the 1-month follow-up. For each measurement time point, CO2 will be compared with its respective predefined threshold. The proportion of monitoring time points at which CO2 is exceeded will be calculated for each week.
Weekly during the 1-month follow-up
Weekly overall proportion of time with VOC threshold exceeded
Prazo: Weekly during the 1-month follow-up
Overall proportion of monitoring time per week during which the VOC threshold is exceeded. VOC will be monitored at predefined measurement intervals during the 1-month follow-up. For each measurement time point, VOC will be compared with its respective predefined threshold. The proportion of monitoring time points at which VOC is exceeded will be calculated for each week.
Weekly during the 1-month follow-up
Weekly overall proportion of time with temperature threshold violated
Prazo: Weekly during the 1-month follow-up
Overall proportion of monitoring time per week during which the temperature threshold is violated. The temperature will be monitored at predefined measurement intervals during the 1-month follow-up. For each measurement time point, the temperature will be compared with its respective predefined threshold. The proportion of monitoring time points at which the temperature is violated will be calculated for each week.
Weekly during the 1-month follow-up
Weekly overall proportion of time with the relative humidity threshold violated
Prazo: Weekly during the 1-month follow-up
Overall proportion of monitoring time per week during which the relative humidity threshold is violated. The relative humidity will be monitored at predefined measurement intervals during the 1-month follow-up. For each measurement time point, the relative humidity will be compared with its respective predefined threshold. The proportion of monitoring time points at which the relative humidity is violated will be calculated for each week.
Weekly during the 1-month follow-up
Weekly overall proportion of time with ambient light (day) threshold violated
Prazo: Weekly during the 1-month follow-up
Overall proportion of monitoring time per week during which the ambient light threshold is violated during the day-time hours. The ambient light will be monitored at predefined measurement intervals during the 1-month follow-up. For each measurement time point, ambient light will be compared with its respective predefined threshold. The proportion of monitoring time points at which ambient light is violated during the day-time hours will be calculated for each week.
Weekly during the 1-month follow-up
Weekly overall proportion of time with ambient light (night) threshold violated
Prazo: Weekly during the 1-month follow-up
Overall proportion of monitoring time per week during which the ambient light threshold is violated during the night-time hours. The ambient light will be monitored at predefined measurement intervals during the 1-month follow-up. For each measurement time point, ambient light will be compared with its respective predefined threshold. The proportion of monitoring time points at which ambient light is violated during the night-time hours will be calculated for each week.
Weekly during the 1-month follow-up
Weekly overall proportion of time with the ambient noise (night) threshold exceeded
Prazo: Weekly during the 1-month follow-up
Overall proportion of monitoring time per week during which the ambient noise threshold is exceeded during night-time hours. The ambient noise will be monitored at predefined measurement intervals during the 1-month follow-up. For each measurement time point, the ambient noise will be compared with its respective predefined threshold. The proportion of monitoring time points at which ambient noise is exceeded during night-time hours will be calculated for each week.
Weekly during the 1-month follow-up

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Ziekenhuis Oost-Limburg

Colaboradores

KU Leuven
Hasselt University
University of Liege
Maastricht University

Investigadores

  • Investigador principal: David Ruttens, MD, PhD, Ziekenhuis Oost-Limburg

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de outubro de 2026

Conclusão Primária (Estimado)

1 de outubro de 2027

Conclusão do estudo (Estimado)

1 de outubro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

17 de agosto de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

27 de agosto de 2026

Primeira postagem (Real)

2 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

27 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • Z-2026041
  • IMR6-00019 (Número de outro subsídio/financiamento: Interreg Meuse-Rhine)
  • UH-2026049 (Outro identificador: CME Hasselt University)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever